PM360 2020 Innovative Startup POLARISqb


Dr. Shahar Keinan, CEO

Quantum computing is not only revolutionizing numerous industries, but changing how we can fight infectious disease. POLARISqb stands apart in the quantum drug discovery space, bringing market-ready methods that use quantum-inspired computing to accelerate the identification of potential molecular assets by up to 90%. Its unique technology can narrow the potential field of candidate molecules from billions to dozens in about the same amount of time that it takes to complete a traditional internet search.

In partnership with Fujitsu Global, POLARISqb used the Digital Annealer, a groundbreaking, quantum-inspired technology, to optimize single or multiple objective searches. The Digital Annealer uses heuristic approaches, rather than brute force, efficiently searching large chemical spaces with unparalleled speed. As a case study, POLARISqb set out to identify potential candidates for treating Dengue Fever, a mosquito borne viral disease without a cure that threatens up to 40% of the world population with potentially deadly complications.

The company’s engineers and chemists targeted the RNA-dependent RNA polymerase protein in the Dengue virus and developed a chemical library of over one billion molecules. Once this library was constructed, they used the Digital Annealer to identify 977 potential drug candidates. The company uses rapid and accurate calculations to scan massive libraries, birthing the potential to identify cures to many diseases that are currently untreatable.

In the world of drug discovery, POLARISqb is slashing timeframes and costs of discovery processes multiple times over. The potential applications for this technology can change the world by developing treatments for previously incurable diseases and pandemics, revolutionizing drug discovery with quantum solutions never before used in the biopharmaceutical industry.


You May Also Like

ELITE 2020 Entrepreneur Michelle Longmire of Medable

Michelle Longmire CEO and Founder Medable Reducing Clinical Trial Timelines Michelle Longmire, MD is ...